Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

Human Reproduction

Volumn 16, Issue 4, 2001, Pages 644-651

  Van Hooren, H G ^a   Fischl, F ^a   Aboulghar, ^a   Mares ^a   Nicollet, B ^a   Behre, H M ^a   Van Der Ven, H ^a   Simon, A ^a   Kilani, Z ^a   Barri, P N ^a   Haberle M ^a   Braat, D D M ^a   Lambalk, N ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Ganirelix; GnRH antagonist; Ovarian stimulation; Recombinant FSH; Triptorelin

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO GROWTH; ENDOCRINE DISEASE; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; NIDATION; OOCYTE; OVARY DISEASE; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PATIENT SATISFACTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 0035070776     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.4.644     Document Type: Article

References (23)

1. Ovarian stimulation with HMG: Results of a prospective randomised phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist certrorelix and the LHRH-agonist buserelin
2. Debate: Triggering the final stage of ovulation using gonadotrophin releasing hormone analogues: Effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase
3. Diagnosis, prevention and management of ovarian hyperstimulation syndrome
4. Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trip-6-luteinizing hormone-releasing hormone and gonadotropins
5. The molecular basis gonadotropin-releasing hormone action
6. New approaches to ovarian hyperstimulation
7. Shortening of treatment with the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran, Antagon) in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon): Results of a controlled, randomized, multicentre trial
8. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH-antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone
9. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, ICH harmonised tripartite guideline
10. A new approach to the management of patients at risk of ovarian hyperstimulation in an in vitro fertilization programme
11. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: Short communication
12. The use of GnRH analogs for induction of the preovulatory gonadotropin surge in assisted reproduction and prevention of the ovarian hyperstimulation syndrome
13. Antagonistic analogs of luteinizing hormone-releasing hormone are mast cell secretagogues
14. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment
15. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
16. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon, Orgalutran®). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
17. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon, Orgalutran®). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
18. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (ganirelix) with minimal histamine releasing properties: Studies in postmenopausal women
19. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction
20. A general parametric approach to the meta-analysis of randomized clinical trials